Long-term follow-up of hepatitis b vaccine in infants of carrier mothers

American Journal of Epidemiology

Volumn 140, Issue 8, 1994, Pages 734-746

  Marion, S A ^a   Pastore, M Tomm ^a   Pi, D W ^b   Mathias, R G ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Canadian Red Cross Society   (Canada)

Author keywords

Communicable disease control; Hepatitis B surface antigens; Hepatitis B virus; Immunization; Immunization schedule; Infant; Vaccination; Viral vaccines

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE;

ACTIVE IMMUNIZATION; ANTIBODY TITER; ARTICLE; CHILD; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; INFANT; INFECTION RISK; INTRAUTERINE INFECTION; MAJOR CLINICAL STUDY; MALE; PASSIVE IMMUNIZATION;

ANALYSIS OF VARIANCE; CARRIER STATE; DISEASE TRANSMISSION, VERTICAL; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B CORE ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMAN; IMMUNIZATION SCHEDULE; INFANT; INFANT, NEWBORN; MALE; REGRESSION ANALYSIS; SEROEPIDEMIOLOGIC STUDIES; SUPPORT, NON-U.S. GOV'T;

EID: 0027992917     PISSN: 00029262     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.aje.a117321     Document Type: Article

References (39)

1. West DJ, Calandra GB, Ellis RW. Vaccination of infants and children against hepatitis B. Pediatr Clin North Am 1990;37:585-97.
2. Beasley RP, Hwang LY, Lee GCY, et al. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet 1983;2: 1099-102.
3. Beasley RP, Hwang LY, Lin CC, et al. Hepatitis B immune globulin (HBIG) efficacy in the interruption of perinatal transmission of hepatitis B virus carrier state. Lancet 1981;2:388-93.
4. Ballem PJ, Stout TD, Elliot M, et al. Review of a province-wide program for the prevention of HBV infection in infants of carrier mothers. (Abstract). Blood 1987;70(Suppl. l):118a.
5. Stevens CE, Toy PT, Tong MJ, et al. Perinatal hepatitis B virus transmission in the United States. JAMA 1985;253:1740-5.
6. Stevens CE, Taylor PE, Tong MJ, et al. Yeast-recombinant hepatitis B vaccine efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmission. JAMA 1987;257:2612-16.
7. Farmer K, Gunn T, Woodfield DG. A combination of hepatitis B vaccine and immunoglobulin does not protect all infants bom to hepatitis B e antigen positive mothers. N Z Med J 1987; 100: 412-14.
8. Waters JR. Universal prenatal screening for hepatitis B, Alberta, 1985-1988. Can Dis Wkly Rep 1989;15:29-32.
9. Poovorawan Y, Sanpavat S, Pongpunlert W, et al. Comparison of a recombinant DNA hepatitis B vaccine alone or in combination with hepatitis B immune globulin for the prevention of perinatal acquisition of hepatitis B carriage. Vaccine 1990;8(Suppl.):S56-9.
10. Theppisai U, Thanuntaseth C, Chiewsilp P, et al. Prevention of hepatitis B infection in infants bom to hepatitis B carrier mothers: low dosage vaccination. Int J Gynaecol Obstet 1990;32: 353-7.
11. Lee CY, Huang LM, Chang MH, et al. The protective efficacy of recombinant hepatitis B vaccine in newborn infants of hepatitis B e antigen-positive hepatitis B surface antigen carrier mothers. Pediatr Infect Dis J 1991;10: 299-303.
12. Ip HMH, Lelie PN, Wong VCW, et al. Prevention of hepatitis B vims carrier state in infants according to maternal serum levels of hepatitis B virus DNA. Lancet 1989;1:406-10.
13. Schalm SW, Mazel JA, de Gast GC, et al. Prevention of hepatitis B infection in newborns through mass screening and delayed vaccination of all infants of mothers with hepatitis B surface antigen. Pediatrics 1989;83:1041-8.
14. Tajiri H, Nose O, Shimizu K, et al. Prevention of neonatal HBV infection with the combination of HBIG and HBV vaccine and its long-term efficacy in infants born to HBeAg positive HBV carrier mothers. Acta Paediatr Jpn 1989;31: 663-8.
15. Resti M, Azzari C, Rossi ME, et al. Five-year follow-up of vaccination against hepatitis B vims in newborns vaccinated with a reduced number of doses. Vaccine 1991;9:15-18.
16. Assateerawatt A, Suvatte V, Tanphaichitr VS. Long term efficacy of hepatitis B immunoprophylaxis in neonates at risk: using different vaccine and schedule. J Med Assoc Thai 1992;75: 328-36.
17. Poovorawan Y, Sanpavat S, Pongpunglert W, et al. Long-term efficacy of hepatitis B vaccine in infants bom to hepatitis B e antigen-positive mothers. Pediatr Infect Dis J 1992;11:816-21.
18. Delage G, Rémy-Prince S, Montplaisir S. Combined active-passive immunization against the hepatitis B vims: five-year follow-up of children bom to hepatitis B surface antigen-positive mothers. Pediatr Infect Dis J 1993;12:126-30.
19. Lieming D, Mintai Z, Yinfu W, et al. A 9-year follow-up study of the immunogenicity and long-term efficacy of plasma-derived hepatitis B vaccine in high-risk Chinese neonates. Clin Infect Dis 1993;17:475-9.
20. Coursaget P, Yvonnet B, Chotard J, et al. Seven- year study of hepatitis B vaccine efficacy in infants from an endemic area (Senegal). Lancet 1986;2:1143-5.
21. Lo KJ, Lee SD, Tsai YT, et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in infants bom to HBeAg-positive HBsAg-carrier mothers. Hepatology 1988;8:1647-50.
22. Theppisai U, Thanuntaseth C, Chiewsilp P, et al. Long-term immunoprophylaxis of hepatitis B surface antigen carrier in infants bom to hepatitis B surface antigen positive mothers using plasma derived vaccine. Asia Oceania J Obstet Gynaecol 1989;15:111-15.
23. Tajiri H, Kozaiwa K, Harada T, et al. Mass protection program of perinatal hepatitis B vims infection in Japan and impact of an optional booster vaccination on its efficacy. Acta Paediatr Jpn 1991;33:323-6.
24. Hwang LY, Lee CY, Beasley RP. Five-year follow-up of HBV vaccination with plasma-derived vaccine in neonates: evaluation of immunogenicity and efficacy against perinatal transmission. In: Hollinger FB, Lemon SM, Margolis HS, eds. Viral hepatitis and liver disease. Baltimore, MD: Williams & Wilkins, 1990:759-61.
25. Sackett DL, Haynes RB, Tugwell P. Clinical epidemiology: a basic science for clinical medicine. Boston, MA: Little, Brown & Co., 1985.
26. Eble K, Clemens J, Krenc C, et al. Differential diagnosis of acute viral hepatitis using rapid, fully automated immunoassays. J Med Virol 1991;33:139-50.
27. Ostrow DH, Edwards B, Kimes D, et al. Quantitation of hepatitis B surface antibody by an automated microparticle enzyme immunoassay. J Virol Meth 1991;32:265-76.
28. Tomm Pastore M. Long-term follow-up of neonates who have been immunized with hepatitis B vaccine. MSc Thesis. Vancouver, British Columbia, Canada: University of British Columbia, 1993.
29. Maynard E, Kane MA, Hadler SC. Global control of hepatitis B through vaccination: role of hepatitis B vaccine in the Expanded Programme on Immunization. Clin Infect Dis 1989; 11 (Suppl. 3):S574-8.
30. White H. A heteroskedasticity-consistent covariance matrix estimator and a direct test for het-eroskedasticity. Econometrica 1980;48:817-38.
31. Dean AG, Dean JA, Burton AH, et al. Epi Info, Version 5: a word processing, database, and statistics program for epidemiology on microcomputers. Stone Mountain, GA: USD, Incorporated, 1990.
32. Norusis MJ. SPSS/PC+ Advanced statistics 4.0 for the IBM PC/XT/AT and PS/2. Chicago, IL: SPSS Inc., 1990.
33. Mehta C, Patel N. StatXact-Turbo, statistical software for exact nonparametric inference, user manual. Cambridge, MA: Cytel Software Corporation, 1992.
34. Stevens CE, Neurath RA, Beasley RP, et al. HBeAg and anti-HBe detection by radioimmunoassay: correlation with vertical transmission of hepatitis B virus in Taiwan. J Med Virol 1979;3:237-41.
35. Zanetti AR, Ferroni P, Magliano EM, et al. Perinatal transmission of the hepatitis B virus and of the HBV-associated delta agent from mothers to offspring in Northern Italy. J Med Virol 1982;9: 139-48.
36. Wainwright RB, McMahon BJ, Bulkow LR, et al. Duration of immunogenicity and efficacy of hepatitis B vaccine in a Yupik Eskimo population. JAMA 1989;261:2362-6.
37. Beasley RP, Trepo C, Stevens CE, et al. The e antigen and vertical transmission of hepatitis B surface antigen. Am J Epidemiol 1977;105: 94-8.
38. Assateerawatt A, Tanphaichitr VS, Suvatte V, et al. Immunogenicity and protective efficacy of low dose recombinant DNA hepatitis B vaccine in normal and high-risk neonates. Asian Pac J Allergy Immunol 1991;9:89-93.
39. Monna T, Kuroki T, Oka H, et al. Prevention of vertical transmission of HBV by administration of hepatitis B vaccine combined with HBIG and long-term follow-up of HBsAb titer. Osaka City Med J 1988;34:9-17.